Based on your answers, heres the best next step: Not sure whether semaglutide or tirzepatide is the better fit
In three double-blind, placebo-controlled trials in the treatment of influenza in patients at least 65 years old, that enrolled 741 subjects (374 received placebo and 362 received TAMIFLU), no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects [see Clinical Studies (14.1)]
these were the most frequently reported AEs across all treatment arms but they were mostly transient and mild/moderate in severity, consistent with the safety profile of the GLP-1RA drug class [8, 18, 24]
When people lose weight, they are healthier, they dont have diabetes and they dont have cardiac conditions, so its just healthier for the patients, so theyre the ones losing out